secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-046043
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Biosciences Q3 2024 operating loss narrows to $2.4M; acquires SOLOSEC, licenses Phexxi in Middle East
--------------------------------------------------------------------------------

- Net product sales $4.5M in Q3 2024, down 12% YoY from $5.1M; operating loss improved 31% to $2.4M.
- Net loss attributable to common stockholders $2.4M ($0.02/sh) vs net income $66.0M ($15.34/sh) in Q3 2023 due to prior-year debt extinguishment gain.
- Acquired global rights to SOLOSEC (secnidazole) 2g oral granules, FDA-approved for BV and trichomoniasis, relaunched as single-dose treatment.
- Licensed Phexxi commercial rights in Middle East to Pharma 1 Drug Store; UAE regulatory submission on track by year-end 2024.
- Aditxt invested $5.0M since May 2024, including $1.3M in Q3 and $2.7M in October 2024, under amended merger agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224046043/0001493152-24-046043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224046043/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-046043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer